Drug-related emergency department visits: external validation of an assessment tool in a general emergency department population
International Journal of Clinical Pharmacy · 2024
DOI: 10.1007/s11096-024-01760-8 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift International Journal of Clinical Pharmacy, 2024. Verfasst von Lisbeth D Nymoen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Diakonhjemmet Hospital Pharmacy, Oslo, Norway. Hauptthemen laut MEDLINE: Emergency Service, Hospital, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Oslo.
Abstract (Originalsprache)
Background
The process of identifying drug-related hospitalisations is subjective and time-consuming. Assessment tool for identifying hospital admissions related to medications (AT-HARM10) was developed to simplify and objectify this process. AT-HARM10 has not previously been externally validated, thus the predictive precision of the tool is uncertain.
Aim
To externally validate AT-HARM10 in adult patients admitted to the emergency department (ED).
Method
This retrospective cross-sectional study investigated 402 patients admitted to the ED, Diakonhjemmet Hospital, Oslo, Norway. A trained 5th-year pharmacy student used AT-HARM10 to assess all patients and to classify their ED visits as possibly or unlikely drug-related. Assessment of the same patients by an interdisciplinary expert panel acted as the gold standard. The external validation was conducted by comparing AT-HARM10 classifications with the gold standard.
Results
According to AT-HARM10 assessments, 169 (42%) patients had a possible drug-related ED visit. Calculated sensitivity and specificity values were 95% and 71%, respectively. Further, positive and negative predictive values were 46% and 98%, respectively. Adverse effects/over-treatment and suboptimal treatment were the issues most frequently overestimated by AT-HARM10 compared with the gold standard.
Conclusion
AT-HARM10 identifies drug-related ED visits with high sensitivity. However, the low positive predictive value indicates that further review of ED visits classified as possible drug-related by AT-HARM10 is necessary. AT-HARM10 can serve as a useful first-step screening that efficiently identifies unlikely drug-related ED visits, thus only a smaller proportion of the patients need to be reviewed by an interdisciplinary expert panel.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Diakonhjemmet Hospital Pharmacy, Oslo, Norway.
- Department of Pharmacy, University of Oslo, Oslo, Norway.
- Department of Internal Medicine, Diakonhjemmet Hospital, Oslo, Norway.
- Diakonhjemmet Hospital Pharmacy, Oslo, Norway. kirstkv@farmasi.uio.no.
- Department of Pharmacy, University of Oslo, Oslo, Norway. kirstkv@farmasi.uio.no.
Förderung
- University of Oslo
Zitieren
APA
Nymoen, L. D., Pettersen, J. L. S., Flatebø, T. E., Øie, E., & Viktil, K. K. (2024). Drug-related emergency department visits: external validation of an assessment tool in a general emergency department population. International Journal of Clinical Pharmacy. https://doi.org/10.1007/s11096-024-01760-8
Vancouver
Nymoen LD, Pettersen JLS, Flatebø TE, Øie E, Viktil KK. Drug-related emergency department visits: external validation of an assessment tool in a general emergency department population. International Journal of Clinical Pharmacy. 2024. doi:10.1007/s11096-024-01760-8
BibTeX
@article{Nymoen2024,
author = {Nymoen, Lisbeth D and Pettersen, Julie L S and Flatebø, Trude E and Øie, Erik and Viktil, Kirsten K},
title = {Drug-related emergency department visits: external validation of an assessment tool in a general emergency department population},
journal = {International Journal of Clinical Pharmacy},
year = {2024},
doi = {10.1007/s11096-024-01760-8}
}
EUVIMED